New drug review
Lirafugratinib
Review section
| Field | Value |
|---|---|
| Drug | Lyrfigtu (lirafugratinib) |
| Indication reviewed | Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma |
| Therapeutic category | Fibroblast growth factor receptor 2 (FGFR2) kinase inhibitors |
| Manufacturer | Elevar Therapeutics |
| Regulatory status | Approved September 23, 2026 |
| Data as of | September 27, 2026 |
| Review status | Draft for pharmacy and therapeutics committee review |
Indications
Table 1. FDA-approved indications
Patient selection by FGFR2 status
Pharmacokinetics
Table 2. Pharmacokinetic parameters
| Generic Name(s) | Bioavailability | Protein Binding | Metabolism | Excretion | Half-Life |
|---|---|---|---|---|---|
| Lirafugratinib | Not reported | “>99%” | “primarily metabolized by CYP3A4 and CYP2J2 and to a lesser extent by non-CYP enzymes in vitro” | “approximately 80% of the dose was recovered in feces (23% unchanged), and 8% was recovered in urine (unchanged lirafugratinib not quantified)” | “23 (34%) hours” |
Drug interactions
Table 3. Major drug interactions
Abbreviations: AUC=area under the plasma concentration-time curve; BCRP=breast cancer resistance protein; Cmax=maximum plasma concentration; CYP=cytochrome P450; OATP=organic anion transporting polypeptide; P-gp=P-glycoprotein
Adverse drug events
Table 4. Adverse drug events reported in 15% or more of patients in REFOCUS
| Adverse Event | Lyrfigtu (N = 116), all grades (%) | Lyrfigtu (N = 116), Grade 3 or 4 (%) |
|---|---|---|
| Nail toxicity | “89” | “12” |
| Palmar-plantar erythrodysaesthesia syndrome | “82” | “33” |
| Alopecia | “66” | “0” |
| Dry skin | “37” | “0” |
| Rash | “34” | “5” |
| Stomatitis | “80” | “12” |
| Dry mouth | “50” | “0” |
| Constipation | “37” | “0.9” |
| Abdominal pain | “28” | “3.4” |
| Diarrhea | “22” | “0.9” |
| Nausea | “21” | “1.7” |
| Vomiting | “16” | “0.9” |
| Dry eye | “53” | “0” |
| Retinal pigment epithelial detachment | “38” | “1.7” |
| Blurred vision | “22” | “0.9” |
| Corneal toxicity | “16” | “0” |
| Infection | “34” | “8” |
| Urinary tract infection | “19” | “0.9” |
| Fatigue | “43” | “3.4” |
| Pyrexia | “18” | “0.9” |
| Edema | “17” | “0” |
| Dysgeusia | “39” | “0.9” |
| Neuropathy peripheral | “18” | “0.9” |
| Hemorrhage | “22” | “2.6” |
| Musculoskeletal pain | “22” | “0” |
| Decreased appetite | “20” | “0” |
| Nasal dryness | “15” | “0” |
Serious adverse reactions, discontinuations, interruptions, and dose reductions
Laboratory abnormalities occurring in 20% or more of patients
Ocular toxicity in the pooled safety population of 385 patients
Dosing and administration
Table 5. Usual dosing regimens
See the current prescribing information for full details.
Dosage in hepatic and renal impairment
Effectiveness
Table 6. Comparative clinical trials
Abbreviations: CI=confidence interval; DoR=duration of response; ECOG=Eastern Cooperative Oncology Group; FGFR=fibroblast growth factor receptor; IRC=independent review committee; NGS=next-generation sequencing; ORR=objective response rate; RECIST=Response Evaluation Criteria in Solid Tumors